About the Company
Expanding immune system stimulation to revolutionize vaccines… That is Inovio’s (NYSE MKT: INO) quest. Stimulating the body’s immune system remains one of the most promising approaches to addressing the unmet needs of cancers, HIV, hepatitis C virus, and other chronic infectious diseases. Our synthetic vaccine technology platform is progressively showing its potential to establish a new paradigm to prevent and treat these life-altering diseases. Our growing pipeline of vaccine candidates based on this technology has now advanced to phase II clinical studies. These vaccines could potentially protect millions of people from sickness or death due to disease. At Inovio, we are playing an integral role in defining the future of medicine. We invite you to join us on our journey: as an investor, a participant in our clinical studies, a partner, or just an interested observer.
PLYMOUTH MEETING, Pa., March 21, 2017 (GLOBE NEWSWIRE) — Inovio Pharmaceuticals, Inc. (INO) announced today the election of George Bickerstaff to its Board of Directors. Mr. Bickerstaff is an internationally recognized expert in finance, healthcare and information technology. He...
Inovio Pharmaceuticals to Report Fourth Quarter and Year End 2016 Financial Results on March 15, 2017
PLYMOUTH MEETING, Pa., March 09, 2017 (GLOBE NEWSWIRE) — Inovio Pharmaceuticals, Inc. (INO) announced today that it will host a conference call and live webcast to discuss its 2016 fourth quarter and year end financial results and provide a...
Inovio’s SynCon® WT1 Cancer Antigen Breaks Tolerance, Highlights Potential for Universal Cancer Immunotherapy
PLYMOUTH MEETING, Pa., Feb. 27, 2017 (GLOBE NEWSWIRE) — Inovio Pharmaceuticals, Inc. (INO) today announced that its SynCon® WT1 cancer immunotherapy was capable of breaking immune tolerance and inducing neo-antigen-like T cell responses to cause tumor regression in pre-clinical...
Inovio and ApolloBio to Collaborate on Development and Commercialization of HPV Pre-cancer Immunotherapy VGX-3100 in Greater China
PLYMOUTH MEETING, Pa., Feb. 13, 2017 (GLOBE NEWSWIRE) — Inovio Pharmaceuticals, Inc. (INO) today announced that it has entered into a collaboration and license agreement providing ApolloBio Corporation (NEEQ:430187) with the exclusive right to develop and commercialize VGX-3100, Inovio’s...